Intravenous iron for the treatment of predialysis anemia

Kidney International, Supplement

Volumn 55, Issue 69, 1999, Pages

  Silverberg, Donald S ^a   Blum, Miriam ^a   Agbaria, Zodi ^a   Schwartz, Doron ^a   Zubkov, Alexander ^a   Yachnin, Tatiana ^a   Iaina, Adrian ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Cardiovascular disease; Dialysis; End stage renal disease; Iron deficiency

Indexed keywords

ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; IRON; IRON DERIVATIVE; UNCLASSIFIED DRUG; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; CHRONIC KIDNEY FAILURE; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; ORAL DRUG ADMINISTRATION; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; BLOOD; BLOOD PRESSURE; CORONARY ARTERY DISEASE; DRUG EFFECT; DRUG HYPERSENSITIVITY; IRON DEFICIENCY ANEMIA; IRON INTAKE; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, ORAL; ANEMIA, IRON-DEFICIENCY; BLOOD PRESSURE; CORONARY DISEASE; DRUG HYPERSENSITIVITY; ERYTHROPOIETIN, RECOMBINANT; HUMANS; INJECTIONS, INTRAVENOUS; IRON; IRON, DIETARY; KIDNEY FAILURE, CHRONIC; RENAL DIALYSIS;

EID: 0032909836     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.055suppl.69079.x     Document Type: Review

References (81)

1. SILVERBERG D, BLUM M, PEER G, IAINA A: Anemia during the predialysis period: A key to cardiac damage in renal failure. Nephron 80:1-5, 1998
2. WIZEMANN V: Coronary artery disease in dialysis patients. Nephron 74:642-651, 1996
3. VALDERRABANO F, JONES EHP, MALLICK NP: Report of management of renal failure in Europe, XXIV, 1993. Nephrol Dial Transplant 10(Suppl 5):1-25, 1995
4. LEVIN A, SINGER J, THOMPSON CR, Ross H, LEWIS M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27:347-354, 1996
5. TSUBAKIHARA Y, HAYASHI T, SHOJI T, OKADA N, NAKANISHI I: Benefits of long term recombinant human erythropoietin therapy in pre-dialysis period on the condition of the patients at the introduction of hemodialysis therapy. (abstract) Nephrology 3:S192, 1997
6. HARNETT JD, KENT GM, FOLEY RN, PARFREY PS: Cardiac function and hematocrit level. Am J Kidney Dis 25(Suppl 1):S3-S7, 1995
7. FOLEY RN, PARFREY PS, HARNETT JD, KENT GM, MURRAY DC, BARRE PE: The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28:53-57, 1996
8. MAYER G, HORL WH: Cardiovascular effects of increasing hemoglobin in chronic renal failure. Am J Nephrol 16:263-267, 1996
9. MOCKS J, FRANKE W, EHMER B, QUARDER O, SCIGALLA P: Epoetin reduces mortality? Clinical trials in 3111 HD patients show a decreased CV risk (abstract) J Am Soc Nephrol 7:222A, 1997
10. MOCKS J, FRANKE W, EHMER B, SCIGALLA P, QUARDER O: Analysis of safety database for long-term epoetin-beta treatment: A metaanalysis covering 3697 patients, in Pathogenetic and Therapeutic Aspects of Chronic Renal Failure, edited by KOCH KM, STEIN S. New York, Dekker, 1997, pp 163-179
11. PORTOLES J, TORRALBO A, MARTIN P, RODRIGO J, HERRERO JA, BARRIENTOS A: Cardiovascular effects of recombinant human erythropoietin in predialysis patients. Am J Kidney Dis 29:541-548, 1997
12. GOLTLOIB L, LUDICER H, MINES M, ACKERMAN J: Iron storage in chronic uremic undialyzed patients. Dial Transplant 12:442B-442E, 1983
13. SCHUSTACK A, MESHIAJ D, WAISS Z, GOTLOIB L: Intramuscular iron replenishment and replacement combined with testosterene enanthate in maintenance hemodialysis anemia: A follow up of up to 8 years on 16 patients. Clin Nephrol 23:303-306, 1985
14. FUDIN R, JAICHENKO J, SHOSTAK A, BENNETT M, GOTLOIB L: Correction of uremic iron deficiency in hemodialyzed patients: A prospective study. Nephron 79:299-305, 1998
15. SILVERBERG DS, IAINA A, PEER G, KAPLAN E, LEVI BA, FRANK N, STEINBRUCH S, BLUM M: Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure in patients not receiving dialysis. Am J Kidney Dis 27:234-238, 1996
16. BEZWODA WR, BOTHWELL TH, CHARLTON RW, TORRANCE JD, MACPHAIL AP, DERMAN DP, MAYET F: The relative dietary importance of haem and non-haem iron. S Afr Med J 64:552-556, 1983
17. DONNELLY SM, POSEN GA, ALI MAM: Oral iron absorption in hemodialysis patients treated with erythropoietin. Clin Invest Med 14:271-276, 1991
18. KOOISTRA MP, VAN NIEMANTVERDRIET EC, ESA, MOL-BEERMANN NM, STRUYVENBERG A, MARX JJM: Iron absorption in erythropoietin-treated hemodialysis patients: Effects of iron availability, inflammation and aluminum. Nephrol Dial Transplant 13:82-88, 1998
19. GOCH J, BIRGEGARD G, DANIELSON BG, WIKSTROM B: Iron absorption in patients with chronic uremia on maintenance hemodialysis and in healthy volunteers measured with a simple oral iron load test. Nephron 73:403-406, 1996
20. DOMOTO DT, MARTIN KJ: Failure of CAPD patients to respond to an oral iron absorption test. Adv Perit Dial 8:101-104, 1992
21. TINAWI M, MARTIN KJ, BASTANI B: Oral iron absorption test in patients on CAPD: Comparison of ferrous sulfate and a polysaccharide ferric complex. Nephron 74:291-294, 1996
22. BODDY K, LAWSON DH, LINTON AL, WILL G: Iron metabolism in patients with chronic renal failure. Clin Sci 39:115-121, 1970
23. FAM AG, HOWEY S, TAYLOR JJ, HOCKEN AG: Iron absorption in chronic renal failure. Proc Eur Dial Transplant Assoc 7:81-85, 1970
24. DELANO BG, MANIS JG, MANIS T: Iron absorption in experimental uremia. Nephron 19:26-31, 1977
25. DENNEBERG T, LINDBERG T, BERG NO, DAHLQVIST A: Morphology, dipeptidases and disaccharidases of small intestinal mucosa in chronic renal failure. Acta Med Scand 195:465-470, 1974
26. ARVANITAKIS C, NAKOS V, KALEKOU-GREKA H, TOURKANTONIS A: Small intestinal function and structure in patients with chronic renal failure. Clin Nephrol 29:235-243, 1988
27. SIMENHOFF ML, SAUKKONEN JJ, BURKE JF, WESSON LG, SCHAEDLER RW, GORDON SJ: Bacterial populations of the small intestine in uremia. Nephron 22:63-68, 1978
28. SIMENHOFF ML, SAUKKONEN JJ, BURKE JF, WESSON LG, SCHAEDLER RN: Amine metabolism and the small bowel in uraemia. Lancet 2:818-821, 1976
29. O'NEIL-CUTTING MA, CROSBY WH: The effect of antacids on the absorption of simultaneously ingested iron. JAMA 255:1468-1470, 1986
30. COOK JD, DASSENKO SA, WHITTAKER P: Calcium supplementation: Effect on iron absorption. Am J Clin Nutr 53:106-111, 1991
31. HALLBERG L, BRUNE M, ERLANDSSON M, SANDBERG A-S, ROSSANDER-HULTEN L: Calcium: Effect of different amounts on nonheme and heme-iron absorption in humans. Am J Clin Nutr 53:112-119, 1991
32. RASTOGI SP, PADILLA F, BOYD CM: Effect of aluminum oxide on iron absorption. (abstract) Kidney Int 8:417A, 1975
33. GOLUBOV J, FLANAGAN P, ADAMS P: Inhibition of iron absorption by Omeprazole in rat model. Dig Dis Sci 36:405-408, 1991
34. IFUDU O, DAWOOD M, FRIEDMAN EA: Relative contributions of body iron status and uremia severity in patients with advanced chronic renal failure. Nephron 77:315-318, 1997
35. AKMAL M, SAWELSON S, KARUBIAN F, GADALLAH M: The prevalence and significance of occult blood loss in patients with predialysis advanced chronic renal failure (CRF), or receiving dialytic therapy. Clin Nephrol 42:198-202, 1994
36. ROSENBLATI SG, DRAKE S, FADEM S, WELCH R, LIFSCHITZ MD: Gastrointestinal blood loss in patients with chronic renal failure. Am J Kidney Dis 1:232-236, 1982
37. REMUZZI G: Bleeding in renal failure. Lancet 1:1205-1208, 1988
38. SILAGY CA, MCNEIL JJ, DONNAN GA, TANKIN AM, WORSAM B, CAMPION K: Adverse affects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 54:84-89, 1993
39. WEIL J, COLIN-JONES D, LANGMAN M, LAWSON D, LOGAN R, MURPHY M, RAWLINS M, VESSEY M, WAINRIGHT P: Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 310:827-830, 1995
40. DAGG JH, SMITH JA, GOLDBERG A: Urinary excretion of iron. Clin Sci 30:495-503, 1966
41. MAGANA L, DHAR SK, SMITH EC, MARTINEZ C: Iron absorption and utilization in maintenance hemodialysis patients: Oral and intravenous routes. Mt Sinai J Med 51:180-183, 1984
42. MARKOVITZ GS, KAHN GA, FEINGOLD RE, COCO M, LYNN RI: An evaluation of the effectiveness of oral iron therapy in hemodialysis patients receiving recombinant human erythropoietin. Clin Nephrol 49:34-40, 1997
43. FISHBANE S, FREI GL, MAESAKA J: Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. Am J Kidney Dis 26:41-46, 1995
44. MACDOUGALL IC, TUCKER B, THOMPSON J, TOMSON CRV, BAKER LRI, RAINE AEG: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 50:1694-1699, 1996
45. ALLEGRA V, MENGOZZI G, VASILE A: Iron deficiency in maintenance hemodialysis patients: Assessment of diagnosis criteria of three different iron treatments. Nephron 57:175-182, 1991
46. SILVERBERG DS, BLUM M, PEER G, KAPLAN E, IAINA A: Intravenous ferric saccharate as an iron a supplement in dialysis patients. Nephron 72:413-417, 1996
47. JONTOFSOHN R, HEINZE V, KATZ N, STUBER U, WILKE H, KUUTHE R: Histidine and iron supplementation in dialysis and pre-dialysis patients. Proc Eur Dial Transplant Assoc 11:391-397, 1974
48. LIM VS, DEGOWIN RL, ZAVALA D, KIRCHNER PT, ABELS R, PERRY P. FANGMAN J: Recombinant human erythropoietin treatment in pre-dialysis patients: A double-blind placebo-controlled trial. Ann Int Med 110:108-114, 1989
49. KOCH KM, KOENE RAP, MESSINGER D, QUARDER O, SCIGALLA P: The use of epoetin beta in anemic predialysis patients with chronic renal failure. Clin Nephrol 44:201-208, 1995
50. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients. Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 61:399-403, 1992
51. VALDERRABANO F: Erythropoietin in chronic renal failure. Kidney Int 50:1373-1391, 1996
52. MASCHIO G: Erythropoietin and systemic hypertension. Nephrol Dial Transplant 10(Suppl 2):74-79, 1995
53. ROTH D, SMITH RD, SCHULMAN G, STEINMAN TI, HATCH FE, RUDNICK NR, SLOAND JA, FREEDMAN BI, WILLIAMS WW, SHADUR CA, BENZ RL, TEEHAN BP, REVICKI DA, SAROKHAN BJ, ABELS RI: Effects of recombinant human erythropoietin in renal function in chronic renal failure predialysis patients. Am J Kidney Dis 24:777-784, 1994
54. SUNDER-PLASSMANN G, HORL WH: Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 10:2070-2076, 1995
55. AL-MOMEN AM, HURAIB SO, MITWALLI AH, AL-WAKEEL J, AL-YAMANI MJMS, ABU-AISHA H, SAID R: Intravenous iron saccharate in hemodialysis patients receiving r-HuEPO. Saudi J Kidney Dis Transplant 5:168-172, 1994
56. NAVARRO JF, TERUEL JL, LIANO F, MARCEN R, ORTUNO J: Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients. Am J Nephrol 16:268-272, 1996
57. GRANOLLERAS C, ZEIN A, OULES R, BRANGER J, FOURCADE J, SHALDON S: Continuous administration of intravenous iron during hemodialysis. Nephrol Dial Transplant 12:1007-1008, 1997
58. FISHBANE S, UNGUREANU V-D. MAESAKA JK, KAUPKE CJ, LIM V, WISH J: The safety of intravenous iron dextran in hemodialysis patients. Am J Kidney Dis 28:529-534, 1996
59. NISSENSON AR, SWAN S, LAMBRECHT LL, ANDERSON P, SCHWEITZER S: Ferric gluconate (Ferlecit) is safe in hemodialysis patients who react to iron dextran. (abstract) J Am Soc Nephrol 7:1460, 1995
60. KURIYAMA S, TOMONARI H, YOSHIDA H, HASHIMOTO T, KAWAGUCHI Y, SAKAI O: Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in non-diabetic patients. Nephron 77:176-185, 1997
61. SPONSEL HT, ALFREY AC, HAMMOND WS, DURR JA, RAY C, ANDERSON RJ: Effects of iron on renal tubular cells. Kidney Int 50:436-444, 1996
62. LANDING BH, GARRICK HC, NADORRA RL, HYMAN CB, WELLS TR: Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. Pediatr Pathol 9:479-500, 1989
63. PARDO-MINDAN FJ, DIEZ J, ESPARZA N, ROBLEDO C: Renal siderosis in patients with heart-valve prostheses: Clinical implications. Nephrol Dial Transplant 5:847-850, 1990
64. MASTRANGELO F, LOREY T, RIZZELLI S, MANISCO G, CORLIANO C, ALFONSO L: Function of the kidney in adult patients with Cooley's disease. Nephron 14:229-236, 1975
65. ADAMS PC, DEUGNIER Y, MOIRAND R, BRISSOT P: The relationship between iron overload, clinical symptoms and age in 410 patients with genetic hemochromatosis. Hepatology 25:162-166, 1997
66. NEFF MS, KIM KE, PERSOFF M, ONESTI G, SWARTZ C: Hemodynamics of ureimc anemia. Circulation 43:876-883, 1971
67. WILLIAMS B, EDMUNDS ME, THOMPSON JR, BURTON PR, FEEHALLY J, WALLS J: Does increasing haemoglobin concentration and haematocrit have a pressor effect in dialysis patients? Nephrol Dial Transplant 4:787-791, 1989
68. KAUPKE CJ, KIM S, VAZIRI ND: Effect of erythrocyte mass on arterial blood pressure in dialysis patients receiving maintenance erythropoietin therapy. J Am Soc Nephrol 4:1874-1878, 1994
69. TERUEL JL, AGUILERA A, MARCEN R, ANTOLI JN, OTERO GG, ORTUNO J: Androgen therapy for anemia of chronic renal failure. Scand J Urol Nephrol 30:403-408, 1996
70. VAZIRI ND, ZHOU XJ, NAGVI F, SMITH J, OVEISI F, WANG ZQ, PURDY RE: Role of nitric oxide resistance in erythropoietin-induced hypertension in rats with chronic renal failure. Am J Physiol 271:E113-E122, 1996
71. SEMPOS CT, LOOKER AC, GILLUM RF: Iron and heart disease: The epidemiologic data. Nutr Rev 54:73-84, 1996
72. OLSON LJ, EDWARDS WD, HOLMES DR, MILLER FA, NORDSTROM LA, BALDUS WP: Endomyocardial biopsy in hemochromatosis: Clinicopathologic correlates in six cases. J Am Coll Cardiol 13:116-120, 1989
73. BESARAB A, KLINE BOLTON W, BROWNE JK, EGRIE JC, NISSENSON AR, OKAMOTO DM, SCHWAB SJ, GOODKIN DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-591, 1998
74. FLEMING LW, HOPWOOD D, SHEPHERD AN, STEWART WK: Hepatic iron in dialysed patients given intravenous dextran. J Clin Pathol 43:119-124, 1990
75. BASSETT ML, HALLIDAY JW, POWELL LW: Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 6:24-29, 1986
76. VAN LENTEN BJ, PRIEVE J, NAVAB M, HAMA S, LUSIS AJ, FOGELMAN AM: Lipid-induced changes in intracellular iron homeostasis in vitro and in vivo. J Clin Invest 95:2104-2110, 1995
77. COMBE C, DELMAS-BEAUVIEUX MC, PEUCHANT E, DE PRECIGOUT V, CARBONNEAU MA, CLERC M, APARICIO M: Antioxidant enzymes and erythropoietin therapy in haemodialysed patients supplemented or not with iron. (abstract) Nephrol Dial Transplant 8:956-957, 1993
78. COLLINS A, EBBEN J, MA J: Frequent IV iron dosing is associated with higher infectious death. (abstract) J Am Soc Nephrol 8:190A, 1997
79. HOEN B, KESSLER M, HESTIN D, MAYEUX D: Risk factors for bacterial infections in chronic hemodialysis adult patients: A multicentre prospective survey. Nephrol Dial Transplant 10:377-381, 1995
80. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30(Suppl 3):S192-S240, 1997
81. SUNDER-PLASSMANN G, SPITZAVER S, HORL WH: The dilemma of evaluating iron status in dialysis patients-limitations of available diagnostic procedures. Nephrol Dial Transplant 12:1575-1580, 1997